Launch of the EU-ToxRisk Commercial Platform

Launch of the EU-ToxRisk Commercial Platform for New Approach Methods (NAMs) in Safety Assessment

The EU-ToxRisk Commercial Platform was launched at the EU-ToxRisk Stakeholder meeting in Egmond, Netherlands on 12 February. The founding group of partners presented on different capabilities and services in integrated testing and assessment including a tiered approach starting with the best use of current data and in silico methods, modelling, read across and in vitro testing based on NAMs. Illustrated solutions included endocrine disruptor screening, liver and kidney investigative toxicology, and neurotoxicity screening. Presentations included:

  • Safety Assessment, Costanza Rovida, CAAT - Europe
  • In Silico Screening, Barry Hardy, Edelweiss Connect
  • High Throughput In Vitro Testing, Bart van der Burg, BDS
  • DILI High Content Screening, Bas ter Braak, DESI
  • Mechanistic investigations in 3D InSight™ Liver Microtissues, Monika Kijanska, InSphero
  • Renal Mitochondrial Toxicity and Phase I/II Metabolism, Paul Jennings, VU
  • Transporter Modelling (Phase III Metabolism), Gerhard Ecker, Phenaris 
  • Neurotoxicity Assessment, Andras Dinnyes, Biotalentum

Since the meeting, the COVID-19 situation has complicated many plans, but we are nevertheless now open to contact and virtual meetings on questions and problems to be solved and will be providing further interesting materials on services offered in the weeks to come. Webinars will be used to provide more detail on particular solutions, as exemplified by the upcoming webinar on transporter modelling presented by Gerhard Ecker. Our passion is solving industrial problems in Safety Assessment, small and large – please contact us with your service request or to discuss how we and our partner group can solve a more difficult problem for you!

Barry Hardy, Edelweiss Connect

About Edelweiss Connect

Edelweiss Connect has developed computer software that helps combine data from many different sources and formats into a useable form for evaluation and re-use. In addition, we have developed other software programs that can use the collected data and data from in vitro tests to predict the safety of chemical compounds in the human body.

Tags

Latest Tweets

Edelweiss Connect (5 weeks ago)
Still time to submit a poster for consideration at the #OpenTox 2022 Virtual Conference The deadline for poster an… https://t.co/XWoGIEpHAn
Edelweiss Connect (2 months ago)
Interested in using a Next Generation #riskassessment Solution? @EdelweissConn plays a leading role in RISK-HUNT3R… https://t.co/XHA2Lr97Bn
Edelweiss Connect (2 months ago)
Join us on August 30 at 16 CEST for the first installment of the #SaferWorldbyDesign: Working days of a cosmetic sa… https://t.co/8yebpqb1Nh
Edelweiss Connect (3 months ago)
We are proud to announce that the catalog of #SaferWorldbyDesign products and services is now available through bot… https://t.co/c6wV90Rh0t
Edelweiss Connect (3 months ago)
SWBD provider SenzaGen obtains OECD approval for GARD®skin #saferskin #skincare #invitro #oecd #machinelearning… https://t.co/OLKn5Jl8Pi

Get in touch

  • Address: Edelweiss Connect GmbH
    Technology Park Basel
    Hochbergerstrasse 60C
    CH-4057 Basel / Basel-Stadt
    Switzerland

USA office

  • Address: Edelweiss Connect Inc
    Research Triangle Park NC
    800 Park Offices Dr
    Durham, NC 27709
    USA